Article Details
Retrieved on: 2025-01-22 14:26:32
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details Bioxytran's partnership with Triton Funds for funding trials related to Alzheimer's, leveraging galectin antagonists. The concepts interlink through the company's focus on antiviral drugs and degenerative diseases, including Alzheimer's.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here